The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting grandly opened on May 31st, local time, in Chicago, USA. As the most influential international event in the field of oncology, this year's conference gathered top global oncology pharmaceutical companies, related enterprises, and scientific researchers to share and discuss the latest research findings together.

ASCO has always been a feast for anti-cancer drugs, where major pharmaceutical companies showcase their latest research findings and present the outstanding clinical data of their drugs. This grand event not only brings a feast of knowledge and a collision of ideas to the global medical and health field, but also plays a pivotal role in promoting the development of the global medical and health industry.

During the ASCO Annual Meeting, OrigiMed showcased a number of research outcomes from collaborations with clinical experts at the conference, presenting innovative and comprehensive precision diagnosis and treatment solutions for tumors to industry peers. In addition, the distinctive booth designed by OrigiMed attracted a continuous stream of visitors. With its rich academic achievements, forward-looking business strategies, and innovative technologies, it engaged in in-depth exchanges with numerous conference attendees and international pharmaceutical companies, jointly discussing the future development trends and innovative directions of the pharmaceutical industry.

Years of Strategic Planning Have Built an Ecosystem for Pharmaceutical Research and Development

Over the years, OrigiMed has been continuously deepening its research and development in the field of innovative oncology drugs, with a comprehensive solution as its core, dedicated to promoting innovation and development of the pharmaceutical industry. We have provided customized solutions for numerous domestic and international biopharmaceutical companies through cutting-edge innovative technologies and powerful data empowerment. In close collaboration with major pharmaceutical companies, we have jointly created a series of services based on precision life science solutions:

NTRK Companion Diagnostics: Collaborated with Bayer to develop innovative pan-cancer companion diagnostics and passed the special review for innovative medical devices.

Post-Marketing Strategic Partnership: Leveraged the strengths of both Takeda and ourselves to build an innovative integrated diagnosis and treatment platform in the field of oncology.

E-Hospital Innovation Alliance: Partnered with AstraZeneca to use OrigiMed Precision Medicine E-Hospital as an innovative platform, providing patients with a comprehensive solution for personalized precision diagnosis and treatment.

Real-World Data Collaboration: Worked with Johnson & Johnson to explore how to use real-world data to support drug development, focusing on innovative applications of this data to accelerate clinical trial processes and improve efficiency of researches.

After years of deep cultivation, OrigiMed has not stopped its pace and has always been committed to innovation and development in the pharmaceutical field. At the ASCO, we had the privilege to engage in in-depth discussions with several multinational pharmaceutical companies from South Korea, India, and other countries on cutting-edge topics such as the use of real-world data to assist in new drug development. Together, we explored how to optimize the drug discovery process using data-driven approaches, to enhance the efficiency of research and development, and reached preliminary cooperation intention in several key areas. We believe that in the near future, through our joint efforts, the global pharmaceutical industry will have another significant and impactful achievement.

Technology Leading the Path of Pharmaceutical Innovation

As a medical company driven by innovative technology, OrigiMed has always placed great emphasis on the development of digital technologies for precision diagnosis and treatment of tumors, and has achieved rich results in this field.

OrigiMed, focusing on patient benefits, continuously explores in the field of precision diagnosis and treatment of tumors: It has successfully established the OrigiMed Precision Medicine E-Hospital. It launched the world's first AI-based precision medicine assistant—SmartMTB, and successfully integrated it into the core processes of patient services, including diagnosis, treatment, follow-up, medication recommendations, clinical trials, and other key stages. In addition, it created the first NTRK clinic which not only provides patient recruitment and clinical enrollment services but also persistently commits to long-term follow-up and meticulous management of patients. By building a comprehensive and closed-loop real-world data collection system, it actively promotes the compliance progress of pharmaceutical companies in real-world research and clinical recruitment.

In the clinical development decision-making for new anti-tumor drugs, OrigiMed deeply understands the core value of multi-dimensional data and considers it as an indispensable key support. To date, we have accumulated tens of thousands of clinical, genomic, and pathological data specific to the Chinese population. By applying cutting-edge AI technology, we continuously optimize the integration and application of data, providing strong guidance for drug development and actively promoting the progress of personalized drug development.

The ASCO Annual Meeting is not only a platform for showcasing the latest research findings but also a bridge that promotes international cooperation and exchange. As a leader in the field of pharmaceutical research and development services in China, OrigiMed has demonstrated our influence and contributions in the field of medical and health through continuous innovation and exploration. We look forward to bringing more innovative results in the future and contributing to the development of the global medical and health industry.